Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experience - Wikidata - wikimedia - TriplyDB

Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experience

Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experience

http://www.wikidata.org/entity/Q34022125

about

Safe discontinuation of nilotinib in a patient with chronic myeloid leukemia: a case report.How I determine if and when to recommend stopping tyrosine kinase inhibitor treatment for chronic myeloid leukaemia.Diagnosis and Treatment of Chronic Myeloid Leukemia in 2015.Cellular and Molecular Networks in Chronic Myeloid Leukemia: The Leukemic Stem, Progenitor and Stromal Cell Interplay.Does the frequency of molecular monitoring after tyrosine kinase inhibitor discontinuation affect outcomes of patients with chronic myeloid leukemia?Treatment-free remission in patients with chronic myeloid leukemia.When to Stop Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia.

P2860

Q34163496-12AF7368-8C8D-49A6-85E1-CF93FEA6F847 Q38206284-A7728AD3-2A16-4D44-82DC-C1BBAFA111ED Q38598820-366A098B-4271-4CC7-94E7-2A787C5A5B86 Q38866390-16CAAC54-9162-4369-B632-017CD2DD0EDA Q38939695-ABF01EE8-E7F3-4976-B07E-0248FAC66D43 Q39423384-17B269FE-58A2-4CFB-96BE-C07646184451 Q53703550-261B1FF3-1120-4C1C-B3D9-1988D65AC8C9

P2860

Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experience

http://www.wikidata.org/entity/Q34022125

description

2013 nî lūn-bûn

@nan

2013 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

name

Patient-driven discontinuation ...... single institution experience

@ast

Patient-driven discontinuation ...... single institution experience

@en

Patient-driven discontinuation ...... single institution experience

@nl

type

label

Patient-driven discontinuation ...... single institution experience

@ast

Patient-driven discontinuation ...... single institution experience

@en

Patient-driven discontinuation ...... single institution experience

@nl

prefLabel

Patient-driven discontinuation ...... single institution experience

@ast

Patient-driven discontinuation ...... single institution experience

@en

Patient-driven discontinuation ...... single institution experience

@nl

P1433

Q34022125-E4DA0D61-F503-4F03-9DA8-E16E8484734B

P1476

Q34022125-D7428523-329B-4B2B-8BDE-80AA0600BE49

P2093

Q34022125-8C5833B9-8FF4-4480-A288-9273D93667C9

Q34022125-CE9100B7-85EB-4386-A1A4-F0FBF96E8FD5

Q34022125-DB60CBC8-BAF5-4A42-AFDB-D14F9294A18A

P2860

Q34022125-128CA62F-1F41-4F02-B3C1-7235DA6CF5A5

Q34022125-195FB49C-D93C-4CE7-91EA-62D948EE6BCF

Q34022125-1AD71D4F-2A60-4F8D-9C82-5FBCDECF56F6

Q34022125-1EB1DBF0-9B2B-41B2-A3AF-44DD5C26A9CA

Q34022125-2C0C5F1D-3F60-403B-8867-F78224021EE7

Q34022125-34B3F4D8-0701-425B-945F-A2927DAD87B1

Q34022125-39EB59D4-875F-423E-BEF1-76FFE2386F7C

Q34022125-486CC62C-1DB8-4337-A911-29ECA4E89D94

Q34022125-53FF9EAC-8545-4B00-B9C4-2D09CBACE2A1

Q34022125-71D202A1-2846-44A7-8A8D-32B7AA2DD51B

P304

Q34022125-0491440A-67C3-4B46-B56E-B6F43F48A154

P31

Q34022125-74D9CFB5-066E-4FF6-A959-0E5AE5059C97

P356

Q34022125-DF1D2484-A03C-413F-9D1B-D58CF4D06A69

P433

Q34022125-1FC262F5-5F1E-416F-89C4-844DEA2896D9

P478

Q34022125-DA15A566-B056-4C76-9C77-373F68EA08EC

P50

Q34022125-08630A08-21C1-4DD9-90FD-171E9C83F984

Q34022125-0BFA53AB-D74F-42B4-A8ED-914E068695F1

Q34022125-2FF169B0-606C-415E-97E4-9EE5FBA06CFD

Q34022125-46C0D52D-6F54-4320-A154-9E35390A3B67

Q34022125-55BBC7BC-5C88-4A46-AEFD-1C734E148D0E

Q34022125-68DD4FAE-4631-47C9-AC02-BF13CA3129DE

Q34022125-6BF06417-04B7-4899-8883-79EF3BE76EE8

Q34022125-93C2FC2F-F7D9-4DD8-A3E6-02CEF7426842

Q34022125-9483F947-5836-4307-B6A3-68243C3062BA

Q34022125-C23F0976-8B2C-4A9C-9DFD-696B42D5BABA

P577

Q34022125-DF7DDE0B-03F8-4B21-AAEE-80B8E62F5FE8

P5875

Q34022125-F14B3547-F076-496E-B0DF-D78EB9E4421E

P698

Q34022125-2E314D7C-580D-4BEC-8CED-7F85DA27D3A9

P921

Q34022125-97BFF26F-0AF2-43E3-B2B2-E3608D8FBF0D

P932

Q34022125-B866C59F-CDE1-4B49-9727-8147C3255973

P356

10428194.2013.831092

P1433

Leukemia & Lymphoma

P1476

Patient-driven discontinuation ...... single institution experience

@en

P2093

Marylou Cardenas-Turanzas

http://www.w3.org/2001/XMLSchema#string

Ohad Benjamini

http://www.w3.org/2001/XMLSchema#string

Preetesh Jain

http://www.w3.org/2001/XMLSchema#string

P2860

Two-sided confidence intervals for the single proportion: comparison of seven methods

Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib

Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimizati

Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia.

Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).

Relapse and late mortality in 5-year survivors of myeloablative allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in first chronic phase.

Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial.

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.

The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors

Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia.

P304

2879-2886

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3109/10428194.2013.831092

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

55

http://www.w3.org/2001/XMLSchema#string

P50

Jorge Eduardo Cortes

Hagop Kantarjian

Gautam Borthakur

Alfonso Quintas-Cardama

Guillermo Garcia-Manero

P577

2013-09-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

255713921

http://www.w3.org/2001/XMLSchema#string

P698

23927391

http://www.w3.org/2001/XMLSchema#string

P921

P932

4127158

http://www.w3.org/2001/XMLSchema#string